ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1902

Gait Alterations Associated with Worsening Knee Pain over 2 Years: A Machine-learning Approach in the MultiCenter Osteoarthritis Study
Abstract Number: 1903

Does Limited Stair Climbing Lead to Poor Future Health? The Relationship Between Short-term Trajectories of Stair Climbing Frequency and Incident Slow Gait Speed over 1 and 2 Years in Adults with Knee Osteoarthritis
Abstract Number: 1904

“Why Does My Knee Hurt After I Got My Knee Replaced?”: Evaluation of Neuropathic-like Symptoms and Objective Signs of Neuropathy Post-Knee Replacement in Patients with Knee Osteoarthritis
Abstract Number: 1905

CD11c+ Expression Associates with IFN-λ Responsiveness in Human B Cells with Clinical Implications for SLE
Abstract Number: 1906

IL-13Ra1-Mediated Signaling Regulates Age-Associated/Autoimmune B-Cell Expansion and Lupus Pathogenesis
Abstract Number: 1907

Increased Otoferlin Expression in B Cells Is Associated with Muscle Weakness in Untreated Juvenile Dermatomyositis: A Pilot Study
Abstract Number: 1908

Interferon (IFN)-Stimulated Gene 15: A Novel Biomarker for Lymphoma Development in Sjögren’s Syndrome
Abstract Number: 1909

Impact of Antimalarial Adherence on Cardiovascular Mortality Among Patients with Newly Diagnosed Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Population-based Study
Abstract Number: 1910

Association Between Clinically Meaningful Improvements in Patient-Reported Outcomes and Stringent Measures of Disease Activity in Patients with Psoriatic Arthritis Treated with Upadacitinib versus Placebo or Adalimumab: Results from a Phase 3 Trial
Abstract Number: 1911

Patient’s and Rheumatologist’s Perspectives on the Burden of Adverse Drug Reactions Attributed to Biologics: A Qualitative Study
Abstract Number: 1912

Meteorological Variables Have Different Effect on Core Measures of Disease Activity in Patients with Rheumatoid Arthritis
Abstract Number: 1913

Patient Perceptions of Telemedicine Use in Rheumatology Clinics During the COVID-19 Pandemic: An Analysis from the COVID-19 Global Rheumatology Alliance
Abstract Number: 1914

Immunomodulatory and Immunosuppressive Medication Modification Among Rheumatology Patients at the Time of COVID-19 Vaccination
Abstract Number: 1915

Risk of Cardiovascular Outcomes with Low-Dose Glucocorticoids in Patients with Rheumatoid Arthritis
Abstract Number: 1916

Antibodies to Malondialdehyde-Acetaldehyde (MAA) Modified Proteins Predict Incident Rheumatoid Arthritis-Associated Interstitial Lung Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].